Financial Results

ASX Announcements 2010

23 August	2010 Annual Report
12 July	LAIV Launched in India
25 June	Rights Issue Update
24 June	Notification of under subscriptions
12 May	Supplementary Prospectus
07 May	Board Changes
12 April	BioDiem Prospectus 2010
12 April	Notice of General Meeting / Proxy Form / Independent Expert Reports
31 March	Pandemic Influenza Vaccine Program Update
30 March	Letter to Shareholders
26 March	Appendix 3B
26 March	Non-Renounceable Pro-Rata Rights Issue Prospectus
25 March	Appendix 3B
25 March	BDM Launches Non-Renounceable Rights Issue
26 February	Shareholder Update February 2010
29 January	Appendix 4C Quarterly Report

ASX Announcements 2009

24 December	BioDiem regains Japanese Rights
27 October	Extension of Co-operative Research Development Agreement
27 October	WHO issues a further sublicence of LAIV
22 October	Appendix 4C Quarterly Report
14 October	LAIV Proof of Concept Trial
24 September	Results of AGM
24 September	AGM Presentation
24 September	Chairman's Address to Shareholders
2 September	WHO Sub-licenses BDM's LAIV Technology
1 September	Agreement with PATH for Prototype Pandemic Influenza Vaccine
31 August	Completion of Phase I Clinical Trial Recruitment for LAIV
24 August	Notice of Meeting & Proxy Form 2009
24 August	Annual Report 2009
31 July	Appendix 4C Quarterly Report
14 July	BioDiem appoints Chief Executive Officer
25 June	Appendix 3B
25 May	BioDiem supports WHO's Global Pandemic Influenza Action Plan
28 April	Appendix 4C Quarterly Report
22 April	Change of Director's Interest Notice - John Brown
24 February	Commencement of Phase I clinical trials for LAIV
5 February	Board Changes
30 January	Appendix 4C Quarterly Report

ASX Announcements 2008

5 December	Phase II results for H5 vaccine confirms safety & immunogenicity
28 November	BioDiem receives 6th Milestone of US$1m for flu vaccine
26 November	Results of AGM 26 November 2008
26 November	CEO AGM Presentation
26 November	Chairman's Address to Shareholders
24 October	Notice of Meeting & Proxy Form 2008
24 October	Annual Report 2008
20 October	Co-operative Research & Development Agreement Extended
16 September	LAIV data presented at Third European Influenza Conference
20 August	Development of protocol for commercial scale manufacture of BDM-E
22 May	Dr Andrew O'Brien appointed CEO
2 April	Appendix 3Y John Brown
29 February	Target market expands for BioDiem's flu vaccine

ASX Announcements 2007

19 December	Appendix 3B
5 December	Final Director's Interest Notice - Robert Borland
5 December	Change of Director's Interest Notice - Hugh Morgan
5 December	Change of Director's Interest Notice - John Brown
3 December	Boardroomradio interview with Dr Andrew O'Brien
30 November	Results of AGM
30 November	CEO AGM Presentation
30 November	Chairman's Address to Shareholders
26 November	BioDiem receives 5th Milestone of US$1m for flu vaccine
30 October	Notice of Meeting / Proxy Form 2007
30 October	Annual Report 2007
22 October	Retirement of non-executive Director, Professor Robert Borland
11 October	Open Briefing 'Equity Placement and Clinical Trial Results'
10 October	Appendix 3B
9 October	BioDiem raises $7m in placement
9 October	BDM-E clinical trial results
27 September	Open Letter to Shareholders
11 September	Final Director's Interest Notice
7 September	BioDiem Board Changes
31 August	BioDiem starts four new Monash studies with BDM-E
14 August	Boardroomradio interview with Tom Williams
13 August	BioDiem completes treatment in phase I/II study of eye drug BDM-E
18 July	Open Briefing 'Implications of Eye Peptide Studies'
2 July	BDM-E repairs retinal damage in mice
27 June	LAIV data presented at Options VI Conference in Canada
4 June	Appendix 3B
4 June	Change of Director's Interest Notice
4 June	Change of Director's Interest Notice
24 May	Russians trial new way of making pandemic flu vaccine
30 April	Recruitment completed for BDM-E clinical trial
26 March	Appendix 3B
9 March	New Patent filed for BDM-E

ASX Announcements 2006

29 November		BioDiem receives 4th Milestone of US$1m for flu vaccine
30 October		Results of AGM
27 October		Chairman's Annual General Meeting address to Shareholders
27 October		Completion of Entitlement Issue
26 October		WHO Influenza Report
26 October		WHO nominates LAIVs for key role in global pandemic plan
27 Sept		Notice of Annual General Meeting
22 Sept		BioDiem appoints new Director
18 Sept		Supplementary Prospectus
18 Sept		Supplementary Prospectus Entitlement Form
30 August		Cooperative Research & Development Agreement
30 August		Request for Trading Halt
29 August		Article in Quarterly Australasian Biotechnology Magazine by AusBiotech
7 August		BioDiem to exhibit at ABIC 2006
7 August		BioDiem Non-renounceable Rights Issue Prospectus
7 August		Appendix 3B
7 August		Letter to Option Holders
7 August		Proposed two for three entitlement issue
17 July		First patients complete BDM-E phase II study
14 July		BioDiem moves into commercialisation phase for BDM-I feed additive
11 April		BIO2006 Chicago - Presentation
6 April		Results in feed additive trials for BDM-I
28 March		Notification of personnel changes
1 March		BioDiem commences Clinical Trial for Diabetic Eye Disease

ASX Announcements 2005

21 December	BioDiem secures $2m AusIndustry Grant Award
1 December	BioDiem announces Clinical Trial in Diabetic Eye Disease
29 November	BioDiem receives 3rd Milestone of US$1m for flu vaccine
28 November	Nobilon's LAIV development program
31 October	Results of AGM
28 October	Chairman's Annual General Meeting address to Shareholders
27 September	Notice of Annual General Meeting
25 August	Hugh Morgan new Chair at BioDiem
25 August	Notification of changes to the Board of BioDiem
29 July	BioDiem receives milestone of US$1m for progress with flu vaccine
30 March	Peter Hodsman appointed R & D Director
15 March	Shareholder Newsletter
17 February	BioDiem appoints new Director
11 January	BioDiem receives first milestone payment from flu vaccine agreement with Akzo Nobel's Nobilon

ASX Announcements 2004

24 November	Results of AGM
24 November	Chairman's Annual General Meeting address to Shareholders
24 November	BioDiem licenses influenza vaccine
19 October	Notice of Annual General Meeting
27 September	BioDiem exercises option to license eye treatment
12 July	BioDiem's BDM-I shows potential for replacing antbiotics in poultry feed
15 April	Pre-clinical results show potential of BioDiem's new avian flu vaccine
24 March	BioDiem's anti-infective promising against major poultry disease
10 February	BioDiem gains approval for US Patent on eye compound
29 January	BioDiem investigates vaccine potential in bird flu
27 January	BioDiem Lists on ASX